CD274 and neoplasm: Immunotherapy blocking the PD-1/PD-L1 regulation axis can efficaciously inhibit its tumor-promoting activity, and the inhibitors of PD-1/PD-L1 have shown clinical efficacy in many tumors over the past decade.